[1]Cai,Zhen-Wei;Zhang,Yongzheng;Borzilleri,RobertM.;Qian,Ligang;Barbosa,Stephanie;Wei,Donna;Zheng,Xiaoping;Wu,Lawrence;Fan,Junying;Shi,Zhongping;Wautlet,BarriS.;Mortillo,Steve;JeyaseelanSr.,Robert;Kukral,DanielW.;Kamath,Amrita;Marathe,Punit;D'Arienzo,Celia;Derbin,George;Barrish,JoelC.;Robl,JeffreyA.;Hunt,JohnT.;Lombardo,LouisJ.;Fargnoli,Joseph;Bhide,RajeevS.[JournalofMedicinalChemistry,2008,vol.51,#6,p.1976-1980]
[2]CurrentPatentAssignee:BRISTOL-MYERSSQUIBBCO-US2007/249610,2007,A1Locationinpatent:Page/Pagecolumn5;9-10
[3]Lobben,PaulC.;Barlow,Evan;Bergum,JamesS.;Braem,Alan;Chang,Shih-Ying;Gibson,Frank;Kopp,Nathaniel;Lai,Chiajen;Laporte,ThomasL.;Leahy,DavidK.;Müslehiddinolu,Jale;Quiroz,Fernando;Skliar,Dimitri;Spangler,Lori;Srivastava,Sushil;Wasser,Daniel;Wasylyk,John;Wethman,Robert;Xu,Zhongmin[OrganicProcessResearchandDevelopment,2015,vol.19,#8,p.900-907]
[4]CurrentPatentAssignee:BRISTOL-MYERSSQUIBBCO-US2007/249610,2007,A1Locationinpatent:Page/Pagecolumn5;11-12
[5]Locationinpatent:schemeortableTran,ScottB.;Lago,MichaelW.;Tian,Yuan;Gong,SharonX.;Batra,Indu;Allentoff,AlbanJ.;Maxwell,BradD.;Bonacorsi,SamuelJ.;Ogan,Marc;Rinehart,J.Kent;Balasubramanian,Balu[Journaloflabelledcompoundsandradiopharmaceuticals,2011,vol.54,#6,p.324-331]
[1]Lobben,PaulC.;Barlow,Evan;Bergum,JamesS.;Braem,Alan;Chang,Shih-Ying;Gibson,Frank;Kopp,Nathaniel;Lai,Chiajen;Laporte,ThomasL.;Leahy,DavidK.;Müslehiddinolu,Jale;Quiroz,Fernando;Skliar,Dimitri;Spangler,Lori;Srivastava,Sushil;Wasser,Daniel;Wasylyk,John;Wethman,Robert;Xu,Zhongmin[OrganicProcessResearchandDevelopment,2015,vol.19,#8,p.900-907]
[1]Lobben,PaulC.;Barlow,Evan;Bergum,JamesS.;Braem,Alan;Chang,Shih-Ying;Gibson,Frank;Kopp,Nathaniel;Lai,Chiajen;Laporte,ThomasL.;Leahy,DavidK.;Müslehiddinolu,Jale;Quiroz,Fernando;Skliar,Dimitri;Spangler,Lori;Srivastava,Sushil;Wasser,Daniel;Wasylyk,John;Wethman,Robert;Xu,Zhongmin[OrganicProcessResearchandDevelopment,2015,vol.19,#8,p.900-907]
Title: Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants.
Journal: Journal of clinical pharmacology 20120601
Title: Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120401
Title: Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120401
Title: Reversible and pH-dependent weak drug-excipient binding does not affect oral bioavailability of high dose drugs.
Journal: The Journal of pharmacy and pharmacology 20120401
Title: Identification of the oxidative and conjugative enzymes involved in the biotransformation of brivanib.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20120101
Title: Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors.
Journal: Cancer chemotherapy and pharmacology 20111201
Title: Malignant peripheral nerve sheath tumour presenting as a pneumothorax.
Journal: The British journal of radiology 20111001
Title: Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110815
Title: Overcoming antiangiogenic resistance.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110815
Title: Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.
Journal: British journal of cancer 20110628
Title: A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20110601
Title: Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20110501
Title: Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110401
Title: Brivanib alaninate for cancer.
Journal: Expert opinion on investigational drugs 20110401
Title: Future treatment option for hepatocellular carcinoma: a focus on brivanib.
Journal: Digestive diseases (Basel, Switzerland) 20110101
Title: Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20101101
Title: Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor.
Journal: Anticancer research 20101101
Title: Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate.
Journal: Breast cancer research and treatment 20101001
Title: Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors.
Journal: European journal of cancer (Oxford, England : 1990) 20100601
Title: The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.
Journal: Molecular cancer therapeutics 20100201
Title: Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Journal: Cancer chemotherapy and pharmacology 20091201
Title: Direct and indirect separations of five isomers of Brivanib Alaninate using chiral high-performance liquid chromatography.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081101
Title: Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20081001
Title: Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).
Journal: Journal of medicinal chemistry 20080327
Title: Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist.
Journal: Cancer research 20070715
Title: Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.
Journal: Journal of medicinal chemistry 20060406
Title: Bhide RS, et al. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo,1-f,2,4triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem, 2006, 49 (7), 2143-2146.
Title: Nakamura I, et al. Correction: Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling. PLoS One. 2015 Nov 3;10(11):e0142355.
Title: Huynh H, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res, 2008, 14(19), 6146-6153.
